Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) have received an average recommendation of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $29.10.

ITCI has been the subject of several analyst reports. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Wednesday, January 3rd. Finally, Royal Bank of Canada initiated coverage on Intra-Cellular Therapies in a research note on Thursday, February 8th. They issued an “outperform” rating and a $33.00 price objective for the company.

How to Become a New Pot Stock Millionaire

Intra-Cellular Therapies stock traded down $0.02 during midday trading on Wednesday, reaching $20.25. 163,303 shares of the stock traded hands, compared to its average volume of 531,795. Intra-Cellular Therapies has a 12 month low of $7.85 and a 12 month high of $25.82. The firm has a market cap of $1,108.37, a PE ratio of -9.56 and a beta of 0.58.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.06). The company had revenue of $5.06 million during the quarter, compared to the consensus estimate of $0.05 million. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 26.67%. Intra-Cellular Therapies’s revenue for the quarter was down 94.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.64) earnings per share. sell-side analysts predict that Intra-Cellular Therapies will post -3.33 earnings per share for the current year.

In related news, VP Lawrence J. Hineline sold 49,700 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $20.02, for a total transaction of $994,994.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael Halstead sold 25,500 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $18.03, for a total value of $459,765.00. Following the sale, the senior vice president now directly owns 191 shares of the company’s stock, valued at $3,443.73. The disclosure for this sale can be found here. 21.00% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth approximately $101,000. SG Americas Securities LLC lifted its stake in shares of Intra-Cellular Therapies by 45.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock worth $190,000 after acquiring an additional 3,794 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $212,000. UBS Asset Management Americas Inc. bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $213,000. Finally, First Mercantile Trust Co. lifted its stake in shares of Intra-Cellular Therapies by 77.3% during the 4th quarter. First Mercantile Trust Co. now owns 15,588 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 6,797 shares during the last quarter. 70.47% of the stock is owned by hedge funds and other institutional investors.

WARNING: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://theolympiareport.com/2018/04/16/intra-cellular-therapies-inc-itci-given-consensus-recommendation-of-buy-by-brokerages.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.